TL/DR –
The Trump administration recently announced the discontinuation of a temporary subsidy that has lowered premiums for Medicare Part D standalone prescription drug plans. The subsidy was initially introduced by the Biden administration to offset expected premium increases following major changes to the Part D benefit, and was supposed to run through at least 2027. The ending of this subsidy could result in higher premiums for some Medicare beneficiaries, with more detailed information about the impact on 2027 premiums anticipated later this year.
“`html
President Trump Announces End to Medicare Part D Subsidy
Recently, the Trump administration has announced that it will cease a temporary subsidy that has been reducing the premiums for standalone prescription drug plans under Medicare Part D. This subsidy was originally put in place by the Biden administration, with the goal of offsetting the expected increase in premiums following significant changes to the Part D benefit. Unless otherwise extended, the subsidy was scheduled to last until at least 2027. Some Medicare beneficiaries could experience higher Part D premiums as a result of this decision.
Understanding the Impact
The decision of cutting the subsidy does not modify the Medicare Part D prescription drug benefit itself. The subsidy was designed to keep the premiums for standalone prescription drug plans under control. Without it, some Medicare recipients could face heightened prescription-drug premiums. The exact impact on premiums will only become clear with more detailed data on 2027 premiums, which will be available this fall.
Background of the Subsidy
Medicare is comprised of three core parts: Part A that covers inpatient hospital care, Part B that covers outpatient medical services, and Part D that provides prescription drug coverage. Beneficiaries can access this coverage either by enrolling in the traditional Medicare, which includes Parts A and B and adding a standalone Part D prescription drug plan, or by signing up for the Medicare Advantage plans. These are subsidized plans offered by private insurers that bundle together hospital, outpatient, and typically, prescription drug coverage.
According to the nonpartisan health policy research organization KFF, over 56 million individuals have enrolled in Part D coverage as of February. Out of these, 44% are enrolled in standalone prescription drug plans and the rest 56% are enrolled through Medicare Advantage plans.
The termination of the temporary subsidy, however, should not affect premiums for Medicare Advantage enrollees as it was specifically targeted to standalone prescription drug plans available to individuals with traditional Medicare.
Changes in the Market
The standalone drug plans are provided by private insurers contracted with the government. The 2022 Inflation Reduction Act introduced a significant overhaul of the Part D benefit, making several changes aimed at making prescription drugs more affordable for seniors with standalone Part D plans.
However, these changes were anticipated to lead to increased premiums, as insurers had to adjust to higher costs. To mitigate this effect, policymakers limited annual increases to the “base beneficiary premium”, used in calculating the actual premiums that people pay. The Inflation Reduction Act caps year-to-year base premium increases at 6% per year through 2029; this provision remains unchanged.
The Biden administration created the temporary subsidy program in 2024 to further stabilize standalone drug-plan premiums starting in 2025. This subsidy, officially known as the Part D Premium Stabilization Demonstration, was renewed by the Trump administration at a lower level for 2026. However, last month the administration announced that the subsidy will not be available for 2027.
This subsidy has cost $9.8 billion over the past two years, as per the Government Accountability Office.
“`
—
Read More US Economic News